Africa: Acoziborole Winthrop, Developed by DNDi and Sanofi, receives European Medicines Agency positive opinion as Three-tablet, Single-Dose Treatment For Most Common Form of Sleeping Sickness

Africa: Acoziborole Winthrop, Developed by DNDi and Sanofi, receives European Medicines Agency positive opinion as Three-tablet, Single-Dose Treatment For Most Common Form of Sleeping Sickness

Kinshasa / Paris / Geneva / Amsterdam — • Recommendation based on Phase II/III study demonstrating up to 96 per cent success rates at 18 months across both early and advanced stages of T.b. gambiense, the most common form of sleeping sickness • The therapy, given as a single dose of three tablets, could offer a simpler…

Read More
Africa: Sierra Leone – Action Pledge to Tackle ‘Unlawful and Abusive’ Treatment of Journalists

Africa: HIV Studies Call for Africa-Specific Data to Optimise Treatment Strategies

Nairobi — New HIV research presented this week at the Conference on Retroviruses and Opportunistic Infections (CROI 2026) has revealed critical evidence gaps that experts say must be urgently addressed to strengthen HIV treatment strategies across Africa. Researchers from the Centre for Epidemiological Modelling and Analysis (CEMA) at the University of Nairobi presented findings from…

Read More
Africa: Sierra Leone – Action Pledge to Tackle ‘Unlawful and Abusive’ Treatment of Journalists

Africa: World Risks Reversing HIV Progress As Children Continue to Face Treatment Gap

Children and adolescents living with HIV-AIDS continue to be left behind in access to early diagnosis, life-saving treatment and care, as shrinking funding threatens to increase their risks and reverse decades of progress, Unicef warned ahead of World AIDS Day. A recently published Unicef-UNAIDS modelling shows that, if programme coverage falls by half, an additional…

Read More
Africa: Sierra Leone – Action Pledge to Tackle ‘Unlawful and Abusive’ Treatment of Journalists

Africa: New Injectable HIV Treatment Shows Promise in Africa, Study Finds

Nairobi — A new study conducted across three African countries has found that an injectable HIV treatment–Cabotegravir/Rilpivirine (CAB LA + RPV LA), administered every two months–is safe, well tolerated, and preferred by most patients. The Month-12 results, drawn from study sites in Kenya, Uganda, and South Africa, offer renewed hope for improved treatment adherence, fewer…

Read More
Africa: Fast Facts – World Risks Reversing HIV Progress As Children Continue to Face Treatment Gap – Unicef

Africa: Fast Facts – World Risks Reversing HIV Progress As Children Continue to Face Treatment Gap – Unicef

New York — Children and adolescents living with HIV continue to be left behind in access to early diagnosis, life-saving treatment, and care, as shrinking funding threatens to increase their risks and reverse decades of progress, UNICEF warned today ahead of World AIDS Day. A recently published UNICEF-UNAIDS modelling shows that, if programme coverage falls…

Read More
Africa: Phase 2 Clinical Trial Results Show Potential to Shorten TB Treatment Time

Africa: Phase 2 Clinical Trial Results Show Potential to Shorten TB Treatment Time

Sorfequiline, previously known as TBAJ-876, was evaluated in combination with pretomanid and linezolid in a randomized, controlled trial in people with drug-sensitive TB COPENHAGEN (November 19, 2025)—New clinical trial results presented by TB Alliance at the Union World Conference on Lung Health show that the novel antibiotic candidate sorfequiline (TBAJ-876), a next-generation diarylquinoline, has the…

Read More